Clinical Trials
Prasinezumab Shows Sustained Motor Progression Benefits in PASADENA Open-Label Extension
The PASADENA trial's open-label extension continues to show that prasinezumab (RO7046015/PRX002) — a monoclonal antibody targeting aggregated α-synuclein — produces a sustained effect on Parkinson's disease motor progression in early-stage participants. The PASADENA Investigators (published in Neurology) report that participants who continued or switched to prasinezumab maintained slower motor decline compared to historical baselines. A separate Phase III trial (NCT07174310) is now actively recruiting to confirm these findings in a larger population. *
ActivPARK Multicenter Cohort Launches Across Europe
A new multicenter clinical cohort study called ActivPARK (NCT06901869) has launched with the long-term goal of maintaining and enhancing functioning, health, and wellbeing in persons with Parkinson's disease (PwPD) through tailored and personalized physical activity interventions. The study will collect real-world activity data across multiple centers, aiming to establish evidence-based exercise prescriptions specific to PD motor subtypes. *
Foslevodopa Real-World Study Enrolling
A real-world evidence study for foslevodopa (NCT07227896) is currently enrolling participants. Foslevodopa is a continuous subcutaneous infusion formulation of levodopa/carbidopa designed to address motor fluctuations by providing stable plasma levels around the clock, potentially reducing OFF time more effectively than oral medications alone. *
Breakthrough Treatments
Japan Approves Stem-Cell Treatment for Parkinson's in World First
In March 2026, Japan became the first country in the world to approve a stem-cell based therapy for Parkinson's disease. The treatment involves the transplantation of dopamine neurons derived from induced pluripotent stem cells (iPSCs) into patients with advanced disease. This landmark approval represents a major milestone in regenerative medicine and could pave the way for similar approvals in the US and EU. *
AI Drug Discovery Shows Promise for Parkinson's
A March 2026 BBC Future report highlighted how artificial intelligence is rapidly accelerating drug development for previously incurable diseases, including Parkinson's. AI platforms are now designing novel α-synuclein aggregation inhibitors and identifying repurposable compounds at a fraction of the traditional timeline and cost. Several biotech firms have already advanced AI-generated candidates into preclinical IND-enabling studies. *
Michael J. Fox Foundation Awards $195M+ in Early 2026 Research Grants
The Michael J. Fox Foundation for Parkinson's Research announced over $195 million in awarded grants during early 2026, spanning treatment development, precision medicine, genetics, and disease biology. The largest-ever funding commitment from the foundation signals aggressive forward momentum toward disease-modifying therapies ahead of the National Plan to End Parkinson's Act implementation. *
Lifestyle Interventions
The SENSS Framework: Integrated Lifestyle Medicine for Parkinson's
A 2026 study published in Frontiers in Neurology introduced the SENSS framework (Stress, Exercise, Nutrition, Sleep, Self-management) as a structured approach to lifestyle interventions for people with Parkinson's disease. The authors argue that singular lifestyle interventions (exercise alone, diet alone) show promise, but the greatest impact comes from integrating multiple domains simultaneously — addressing stress management alongside physical activity and nutritional support. The framework is designed for use in clinical and community settings alike. *
Lancet Perspective Highlights Lifestyle Medicine as PD Standard of Care
A Lancet Neurology perspective article (June 2026) endorsed the integration of lifestyle medicine — including structured exercise, Mediterranean-style dietary patterns, stress reduction, and sleep optimization — as a complement to pharmacological treatment in Parkinson's. The piece, responding to the SENSS framework proposal, calls for clinical guidelines to incorporate lifestyle interventions as a formal component of standard Parkinson's care rather than an optional adjunct. *
National Plan to End Parkinson's Act Advances Implementation
As of May 2026, the National Plan to End Parkinson's Act is moving into its active implementation phase, creating a coordinated national strategy to improve research, care, and prevention. The plan brings together NIH, FDA, patient advocacy groups, and academic medical centers to accelerate progress on multiple fronts simultaneously. *
Emerging Research
Brain Network Driver of Parkinson's Disease Identified
An international study published in February 2026 identified a specific brain network as the core driver of Parkinson's disease progression. Researchers found that this network becomes abnormally over-connected in PD patients, disrupting not just motor control but also cognition and autonomic function. This network-level understanding could open entirely new therapeutic targets beyond dopamine replacement. *
α-Synuclein Biological Staging Framework Advances
A comprehensive review in the Journal of Neurochemistry (2026) outlines an updated biological framework for Parkinson's disease centered on α-synuclein aggregation, transmission, and propagation. The framework proposes that disease staging should move beyond clinical symptoms to incorporate α-synuclein-related biomarkers — enabling earlier diagnosis, better patient stratification for clinical trials, and more precise measurement of treatment response. This represents a shift toward "precision neurology" in PD. *
Novel α-Synuclein Targeting Approaches Advance Through Pipeline
A Science Direct review (2026) catalogued the expanding landscape of α-synuclein-targeting therapeutics in development, including: - Antisense oligonucleotides (ASOs) designed to reduce α-synuclein mRNA translation - Antibody-based immunotherapies (prasinezumab, semorinemab, and next-generation candidates) - Small-molecule aggregation inhibitors disrupting the liquid-to-solid phase transition of α-synuclein - Gene therapy approaches using AAV vectors to deliver protective genes *
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.